← Back to Analyst Consensus 
AVBP Buy
ArriVent BioPharma, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 8 reiterations from 7 firms
Next Earnings
Nov 18, 2026 (23 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 20, 2026 | B. Riley Securities | maintain | Buy → Buy | — | 55% |
| Oct 16, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Oct 8, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Oct 7, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Oct 7, 2026 | Jones Trading | maintain | Buy → Buy | — | 50% |
| Oct 7, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Oct 7, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Oct 7, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Aug 17, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 13, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 13, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Aug 13, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| May 29, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| May 13, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Apr 24, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 23, 2026 | B. Riley Securities | maintain | Buy → Buy | — | 55% |
| Mar 6, 2026 | Oppenheimer | reiterate | Outperform → Outperform | — | 52% |
| Mar 6, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 6, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Dec 23, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Dec 10, 2025 | BTIG | initiate | — → Buy | $45 | 52% |
| Nov 25, 2025 | Truist Securities | initiate | — → Buy | $43 | 54% |
| Nov 11, 2025 | Citigroup | maintain | Buy → Buy | $31 | 54% |
| Aug 12, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $42 | 44% |
| Aug 12, 2025 | Citigroup | maintain | Buy → Buy | $33 | 54% |
| Jul 22, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Jun 25, 2025 | Clear Street | initiate | — → Buy | $32 | 48% |
| Jun 24, 2025 | Oppenheimer | maintain | Outperform → Outperform | $44 | 52% |
| Jun 24, 2025 | Guggenheim | reiterate | Buy → Buy | $45 | 52% |
| May 20, 2025 | Jones Trading | initiate | — → Buy | $40 | 50% |
| May 14, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| Mar 20, 2025 | B. Riley Securities | initiate | — → Buy | $37 | 55% |
| Mar 10, 2025 | Guggenheim | initiate | — → Buy | $45 | 52% |
| Mar 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $39 | 44% |
| Jan 22, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $39 | 44% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Sep 11, 2024 | Citigroup | maintain | Buy → Buy | $36 | 54% |
| Sep 10, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $39 | 52% |
| Sep 10, 2024 | Goldman Sachs | maintain | Buy → Buy | $38 | 54% |
| Sep 10, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $36 | 44% |
| Aug 16, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $30 | 44% |
| Aug 15, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $35 | 52% |
| Jun 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| May 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Apr 30, 2024 | HC Wainwright & Co. | initiate | — → Buy | $25 | 44% |
| Feb 20, 2024 | Citigroup | initiate | — → Buy | $30 | 54% |
| Feb 20, 2024 | Jefferies | initiate | — → Buy | $35 | 52% |
| Feb 20, 2024 | Goldman Sachs | initiate | — → Buy | $27 | 54% |
Price Target Trend
Apr 23, 2026 Oct 26, 2026
EPS Estimates
+1q —
0y —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days